Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

After leading Japan’s largest drugmaker for 11 years, Takeda CEO Christophe Weber plans to step down in June of 2026. He will ...

The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...

I am excited to guide Takeda through the next phase, together with our exceptional and talented people, while staying true to ...

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025Management ViewChristophe Weber, CEO, announced his retirement ...

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...

Take­da CEO Christophe We­ber will step down next June af­ter more than 10 years lead­ing the Japan­ese drug­mak­er. Julie ...

Concurrently, the company also announced the decision to appoint Julie Kim as the Chief Executive Officer, succeeding Christophe Weber, who plans to retire from the position in June 2026. Kim ...